New hope for adults with Tough-to-Treat leukemia
NCT ID NCT05157971
Summary
This study is testing the safety and best dose of a drug called venetoclax when added to a standard, intensive chemotherapy regimen for adults newly diagnosed with a type of blood cancer called B-cell acute lymphoblastic leukemia. The goal is to see if this combination can be tolerated and help control the disease. It is enrolling up to 24 adults aged 18-54.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B ACUTE LYMPHOBLASTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
City of Hope Medical Center
RECRUITINGDuarte, California, 91010, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.